Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1 alpha and Inhibition of VEGFR2 and TRKA

作者：Oh Taek In; Lee Yoon Mi; Nam Taek Jin; Ko Young San; Mah Shinmee; Kim Jinhee; Kim Younghoon; Reddy Rallabandi Harikrishna; Kim Young Jun; Hong Sungwoo; Lim Ji Hong

来源：International Journal of Molecular Sciences, 2017, 18(10): 2074.

DOI：10.3390/ijms18102074

• fascaplysin
• survivin
• VEGFR2
• TRKA
• TRAIL

Fascaplysin has been reported to exert anti-cancer effects by inhibiting cyclin-dependent kinase 4 (CDK4); however, the precise mode of action by which fascaplysin suppresses tumor growth is not clear. Here, we found that fascaplysin has stronger anti-cancer effects than other CDK4 inhibitors, including PD0332991 and LY2835219, on lung cancer cells that are wild-type or null for retinoblastoma (RB), indicating that unknown target molecules might be involved in the inhibition of tumor growth by fascaplysin. Fascaplysin treatment significantly decreased tumor angiogenesis and increased cleaved-caspase-3 in xenografted tumor tissues. In addition, survivin and HIF-1 alpha were downregulated in vitro and in vivo by suppressing 4EBP1-p70S6K1 axis-mediated de novo protein synthesis. Kinase screening assays and drug-protein docking simulation studies demonstrated that fascaplysin strongly inhibited vascular endothelial growth factor receptor 2 (VEGFR2) and tropomyosin-related kinase A (TRKA) via DFG-out non-competitive inhibition. Overall, these results suggest that fascaplysin inhibits TRKA and VEGFR2 and downregulates survivin and HIF-1 alpha, resulting in suppression of tumor growth. Fascaplysin, therefore, represents a potential therapeutic approach for the treatment of multiple types of solid cancer.

• 出版日期2017-10